KEY PATHWAYS AND EMERGING PLAYERS IN HUMAN MELANOMA DEVELOPMENT AND PROGRESSION

1)Ianaro AI. 2)Panza EP. 3)De cicco PD. 4)Armogida CA. 5)Ercolano GE. 6)Cirino GC.

University of Naples Federico II

Melanoma is the most common form of skin cancer. Given its high mortality, the interest in the search of preventive measures is growing significantly. Hydrogen sulfide (H2S) is a gaseous signalling molecule that plays important roles in a variety of biological functions in health and disease (Paul & Snyder, 2015). Emerging data indicate that H2S is also involved in the regulation of tumor cell biology (Hellmich MR, Szabo C. 2015). However, the effects of H2S on cancer are controversial and still unclear. It has been shown that H2S induces DNA damage and alter cell cycle in various mammalian cells. Endogenously produced or exogenously released H2S has a role in the accumulation or proliferation of cells and further may provide the fundamentals for development of a novel therapeutic approach in conditions associated with uncontrolled cell growth (Baskar and Bian, 2011). However, the potential biological and clinical significance of H2S are subject of intense debate in recent years and despite considerable progress in our understanding about H2S, much still needs to be learned about their production at the site of tissue injury and its downstream signalling pathways on cell growth. It is also important to emphasize that in the recent literature different roles have been attributed in several types of cancer to CBS-derived H2S and to CSE-derived H2S. Moreover many of the biological responses to H2S follow a biphasic dose-response: while low concentrations of H2S are responsible of physiological and cytoprotective effects, high concentrations result cytotoxic (Szabo, 2016). We have recently demonstrated that the metabolic pathway I-cysteine/CSE/H2S is involved in human melanoma progression and that natural and synthetic H2S releasing agents display anti-tumoral effect (Panza et al., 2015). Our results establish H2S-donors as new potential agents in the treatment of human metastatic melanoma and represent a very promising strategy to improve the fight against cancer.

Paul BD & Snyder SH, (2015). Trends Biochem Sci. 40, 687-700.

Hellmich MR, Szabo C. (2015). Handb Exp Pharmacol. 230:233-41.

Baskar and Bian, (2011). Eur J Pharmacol. 656(1-3):5-9.

Szabo C., Nat Rev Drug Discov. (2016). 15(3):185-203.

Panza et al., (2015). Pigment Cell Melanoma Res. 28(1):61-72.